Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over Novo in the weight-loss drugs market.
Novo Nordisk Shares Tumble 8% on CagriSema Weight Loss Miss
Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight loss drug CagriSema. The Redefine 2 trial
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of 22.7 per cent of their body weight. That was only marginally ahead of results for Mounjaro, an existing rival treatment made by Eli Lilly.
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks. The data is seen as crucial for the future potential for its experimental next-generation obesity drug,
Novo Nordisk's CagriSema: A Breakthrough in Weight Loss for Type 2 Diabetes
Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15.
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk's CagriSema: A Weight-Loss Hopeful Under Market Scrutiny
Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares dropped due to lower-than-expected weight loss,
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
MedCity News4d
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss
The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...
BioSpace10d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...